Stephen Phillips, DO
Urology · State College, PANPI 1508123407
Payments from drug & device makers
Across 294 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- AbbVie$897
- Sumitomo Pharma America, Inc.$588
- Johnson & Johnson$454
- Endo Pharmaceuticals Inc.$253
- C. R. Bard, Inc. & Subsidiaries$231
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,15996%
- Education$2394%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 80 | $1,320 |
| AbbVie(2 entities) | 53 | $897 |
| Sumitomo Pharma America, Inc. | 31 | $588 |
| Johnson & Johnson | 26 | $454 |
| Endo Pharmaceuticals Inc. | 13 | $253 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $231 |
| Urogen Pharma, Inc. | 13 | $220 |
| Endo USA, Inc. | 9 | $205 |
| Ferring Pharmaceuticals Inc. | 12 | $188 |
| Bayer | 8 | $152 |
| Pfizer | 10 | $146 |
| Tolmar, Inc. | 4 | $98 |
| Merck | 4 | $78 |
| Intuitive Surgical | 1 | $72 |
| Baxter Healthcare | 1 | $64 |
| KARL Storz Endoscopy-america | 2 | $58 |
| AstraZeneca | 2 | $44 |
| Urovant Sciences Inc | 3 | $43 |
| Boston Scientific | 2 | $39 |
| Axonics, Inc. | 2 | $36 |
| Myovant Sciences Inc. | 2 | $32 |
| Photocure Inc | 2 | $30 |
| Procept Biorobotics Corporation | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Olympus America Inc. | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Dentsply IH Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $15 |
How this compares
$5,398 in reported general payments places this provider in the 65th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 30 | $13,337 |
| EliquisApixaban | 13 | $7,136 |
| GemtesaVibegron | 12 | $6,104 |
| Tamsulosin Hcl | 421 | $4,042 |
| Finasteride | 287 | $2,550 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 18 | $2,431 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $756 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $651 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 27 | $579 |
| Ciprofloxacin Hcl | 137 | $516 |
| Cephalexin | 171 | $415 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 17 | $409 |
| Oxybutynin Chloride | 79 | $404 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 124 | $334 |
| Dutasteride | 21 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,320 | $13,33730 claims |
| PfizerEliquis | $146 | $7,13613 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $588 | $6,10412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 596 urology providers in Pennsylvania.
Other urology in State College
- Laurence BelkoffBala Cynwyd$18.7M
- Paul SieberLancaster$12.6M
- Costas LallasPhiladelphia$3.6M
- John AndersonBethlehem$2.1M
- Jodi MaranchiePittsburgh$1.2M
- Kenneth LessansLancaster$943K
- Stanley MalkowiczPhiladelphia$882K
- Demetrius BagleyPhiladelphia$739K
- Gregory TasianPhiladelphia$645K
- Eugene PietzakPhiladelphia$544K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.